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Abstract: Cancer is a multifactorial and
multistep process. Conventional cytogenetics
has become a major working field in cancer
research. Chromosome rearrangements are
recognized as critical in the pathogenesis of
human cancer. Molecular biology and
molecular cytogenetics technology have
increased our ability to identify genetic
alterations in cancer cells. Polymerase chain
reaction (PCR), fluorescence in situ
hybridization (FISH), oligonucleotide-primed
in situ DNA synthesis (PRINS) are the most
common molecular cytogenetic procedures in
cancer research but they have limits with
precise localization in their principles in
cancer researching. However, comparative
genomic hybridization (CGH) is a powerful
molecular cytogenetic technique which allows
the analysis of chromosomal gains and losses
in tumor cells. In this technique, normal
metaphase chromosomes are hybridized with
differentially fluorescence-labeled genomic
DNAs (tumor with green and normal with
red), and analyzed with fluorescence
microscopy. The chromosomal locations of
amplifications and deletions in the DNA
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Introduction
The genetic basis of neoplasia is well established, and
chromosomal alterations are recognized as critical in the
pathogenesis of human cancer. Cellular oncogenes, tumor
suppressor genes, DNA mismatch repair genes, and genes
associated with cell aging or apoptosis can be affected by
translocations, inversions, deletions, and aberrant regions
of gene amplification (1-8). Molecular biology and
cytogenetics technology have increased our ability to
detect genomic instabilities in cancer cells, to determine
the mechanism(s) responsible for their occurrence, and to
assess their role in the pathogenesis of neoplasia (9-12).
Polymerase chain reaction (PCR) and fluorescence in
situ hybridization (FISH) are the most powerful molecular
cytogenetic techniques for detecting genetic alterations in

sequences between the normal and tumor
DNAs that were not detected by conventional
cytogenetic analysis are thus revealed. The
CGH has also made retrospective studies with
archival
tumor
samples
possible.
Conventional cytogenetic analysis of solid
tumors is technically very difficult and
requires a large number of viable cells.
Therefore, complete genetic description
which is considered to be an important
diagnostic criteria is limited in tumors. The
CGH and other new techniques such as multifluor and spectral karyotyping are required
to analyze the whole genome of the tumor.
The CGH may have widespread uses in the
detection and identification of chromosomal
gains and losses, the analysis of the clonal
evolution of cancer, the implication of specific
genes and regions in cancer progression, the
classification of chromosomal aberrations in
cancer genetics, and prenatal diagnosis
clinical genetics
Key Words: Cancer, comparative genomic
hybridization(CGH), molecular cytogenetics,
genomic instability

cancer cells. Nonisotopic in situ hybridization technique
(NISH) and especially oligonucleotide-primed in situ DNA
synthesis (PRINS), are alternative procedures to the
conventional in situ hybridization (13-21).
Chromosome banding has been used to recognize
chromosomal abnormalities. However, chromosome
banding resolution has limits, as many cryptic changes
involving small chromosome segments and markers
cannot be resolved. FISH is the most efficient and
reproducible approach for precise localization of single
sequences within metaphase chromosomes. Among the
most recent additions to the FISH repertoire are
comparative genomic hybridization (CGH), for detecting
changes (losses and gains) in DNA copy throughout the
tumor genome (22-24), and two new methods namely
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combinatorial multi-fluor FISH and multicolor spectral
karyotyping (25, 26). Therefore, in this review, we shall
explain the basic principles of CGH for our scientists who
work in the field of cancer research.
Comparative Genomic Hybridization (CGH)
The CGH technique is a fluorescence in situ
hybridization technique that allows the detection and
mapping of chromosome imbalances in a tumor genome
relative to a normal genome, using total genomic DNA as
a probe (22-24). Delineation of genetic changes in solid
tumors has proved difficult because of the complexity of
the karyotype and difficulties in chromosome
preparation. Molecular genetics and molecular
cytogenetics have provided an insight into the
organization of specific regions. However, CGH makes the
analysis of whole genomes possible. CGH is an analytic
method based on FISH and digital fluorescence ratio
measurements that enables one to compare
cytogenetically the entire genome of malignant and
normal cells, as well as to map gains and losses of DNA in
tumor cells. Recently, CGH has been used to analyze the
genomic alterations in several malignant tumors (27-37).
CGH has also made retrospective studies with small
amounts of the archival tumor samples possuble (38-40).
Amplifications and deletions detected by CGH analysis
might reveal any oncogene(s) or tumor suppressor
gene(s) playing an important role in tumorigenesis.
Digital Image Analysis
The hybridization is analyzed by using a digital image
analysis system based on a microscope equipped with a
cooled CCD camera and a filter system. Excitation of each
fluorochrome is accomplished by using these filters in a
computer-controlled filter wheel. Three fluorochromes
(DAPI, SpectrumGreen, and SpectrumRed) images are
properly registered and processed with a workstation
using software for pseudocolor display. Three color
images are used to visualize the color changes along the
metaphase chromosomes. A quantitative analysis of green
and red flourescence intensities is performed by the
above mentioned software. Local background

fluorescence is determined for each chromosome and
subtracted from the green and red images before
analysis. All profiles are normalized that the overall
green-to-red ratio for the entire metaphase is set at 1.0
(41-43).
Interpretation of CGH Images
Ten metaphases are analyzed for the chromosomal
locations of DNA sequence gains and losses. These regions
are determined by using green-to-red fluorescence
intensity ratio profiles. The definition increase and loss of
DNA-sequence copy number in tumors is based on a
comparison of normal DNAs labeled with two different
colors according to the described protocols (42, 43). The
decision limits of the green-to-red ratios are determined
for the decrease in the DNA copy number < 0.75, and for
the increase in the DNA copy number >1.25, respectively
(these ranges can change according to the software and
laboratory conditions). Processing and evaluation of CGH
analysis has been described in detail previously (41-43).
Conclusion
Conventional cytogenetic analysis of solid tumors is
technically very difficult and requires a large number of
viable cells. Therefore, complete genetic description,
which is considered to be an important diagnostic criteria,
is limited in tumors. CGH and other new techniques;
multi-fluor and spectral karyotyping are required to
analyze the whole genome of tumor samples.
The CGH technique will have widespread use in (1)
the detection of consistent chromosomal gains and losses
in tumors, (2) the implication of specific genes and
regions of the genome in cancer progression, (3) the
analysis of clonal evolution of cancer, (4) the dissection of
genetic changes in experimantal models of tumor
progression, (5) the diagnostic evaluation and refined
classification of chromosomal aberrations in cancer
genetics, and (6) prenatal diagnosis and clinical genetics
(44). For these applications, the CGH strategies and
methodologies must be optimized with new research
programs.
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